Philip B. Gorelick , Shakaib Qureshi , Muhammad U. Farooq
{"title":"Management of blood pressure in stroke","authors":"Philip B. Gorelick , Shakaib Qureshi , Muhammad U. Farooq","doi":"10.1016/j.ijchy.2019.100021","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>In this review and opinion piece, we discuss recent United States (US)-based guidance statements on the management of BP in stroke according to stroke type and stage of stroke.</p></div><div><h3>Methods</h3><p>We reviewed the most recent guidance statements on BP control from United States (US)-based organizations such as the American Heart Association/American Stroke Association (AHA/ASA) and American College of Cardiology (ACC), and articles available to the authors in their personal files.</p></div><div><h3>Results</h3><p>The key BP target before starting alteplase (t-PA) is < 185/110 mm Hg, and the maintenance BP after tPA administration is < 180/105 mm Hg. For IPH patients with systolic BP between 150 and 220 mm Hg and no contraindication to acute BP reduction therapy, acute lowering to 140 mm Hg systolic BP is safe. For persons with small vessel or lacunar cerebral ischemia, a reasonable BP lowering target is < 130 mm Hg systolic. For primary stroke prevention, the target BP for those with hypertension is < 140/90 mm Hg and self-measured BP is recommended to assist in BP control. Recent study and guidance suggest a BP target of <130/80 mm Hg for both primary and recurrent stroke prevention. BP control is reasonable for the prevention of cognitive decline or dementia.</p></div><div><h3>Conclusions</h3><p>BP targets for the proper management of stroke vary by chronological stage of stroke and by stroke subtype. Furthermore, consideration should be given to control of BP variability, especially in the acute phases of stroke, as it may play a role in conferring longer term outcomes.</p></div>","PeriodicalId":36839,"journal":{"name":"International Journal of Cardiology: Hypertension","volume":"3 ","pages":"Article 100021"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ijchy.2019.100021","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cardiology: Hypertension","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590086219300217","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 9
Abstract
Objective
In this review and opinion piece, we discuss recent United States (US)-based guidance statements on the management of BP in stroke according to stroke type and stage of stroke.
Methods
We reviewed the most recent guidance statements on BP control from United States (US)-based organizations such as the American Heart Association/American Stroke Association (AHA/ASA) and American College of Cardiology (ACC), and articles available to the authors in their personal files.
Results
The key BP target before starting alteplase (t-PA) is < 185/110 mm Hg, and the maintenance BP after tPA administration is < 180/105 mm Hg. For IPH patients with systolic BP between 150 and 220 mm Hg and no contraindication to acute BP reduction therapy, acute lowering to 140 mm Hg systolic BP is safe. For persons with small vessel or lacunar cerebral ischemia, a reasonable BP lowering target is < 130 mm Hg systolic. For primary stroke prevention, the target BP for those with hypertension is < 140/90 mm Hg and self-measured BP is recommended to assist in BP control. Recent study and guidance suggest a BP target of <130/80 mm Hg for both primary and recurrent stroke prevention. BP control is reasonable for the prevention of cognitive decline or dementia.
Conclusions
BP targets for the proper management of stroke vary by chronological stage of stroke and by stroke subtype. Furthermore, consideration should be given to control of BP variability, especially in the acute phases of stroke, as it may play a role in conferring longer term outcomes.
目的在这篇综述和观点文章中,我们讨论了最近基于美国的根据卒中类型和卒中阶段管理卒中患者BP的指导声明。方法我们查阅了美国心脏协会/中风协会(AHA/ASA)和美国心脏病学会(ACC)等美国组织关于血压控制的最新指导声明,以及作者个人档案中可获得的文章。结果阿替普酶(t-PA)启动前的关键血压指标为<185/110 mm Hg, tPA给药后维持血压<对于收缩压在150 - 220毫米汞柱之间且无急性降压治疗禁忌症的IPH患者,急性降压至140毫米汞柱是安全的。对于小血管或腔隙性脑缺血患者,合理的降压目标为<收缩压130mmhg。对于初级脑卒中预防,高血压患者的目标血压为<建议140/90毫米汞柱和自测血压,以帮助控制血压。最近的研究和指南建议原发性和复发性卒中预防的血压目标为130/80 mm Hg。控制血压对于预防认知能力下降或痴呆是合理的。结论不同的脑卒中时间分期和不同的脑卒中亚型对脑卒中合理治疗的血压指标不同。此外,应考虑控制血压变异性,特别是在中风的急性期,因为它可能在授予长期结果中发挥作用。